Exhibit 10.1
SETTLEMENT AGREEMENT
This Settlement Agreement (the “Settlement Agreement”) is entered into as of October 18, 2023 by and between
Collectively, Acasti and AKBM may be referred to as the “Parties”.
WHEREAS, on the 25th of October 2019, the Parties entered into a Supply Agreement for the sale and purchase of 40 metric tons of RKO (the “Supply Agreement”; all capitalized terms not defined herein shall have the meaning set forth in the Supply Agreement), and;
WHEREAS, after having taken delivery of 4 metric tons of RKO and paid AKBM USD 500,000, a dispute arose between the Parties as to whether Acasti was obligated to take delivery of the remaining RKO, and;
WHEREAS, since then there have been discussions and negotiations between the Parties, and;
WHEREAS, the Parties desire to amicably settle and resolve all outstanding claims and disputes arising under the Supply Agreement without the need for litigation.
NOW THEREFORE, in consideration of the foregoing and other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, Acasti and AKBM agree as follows:
Exhibit 10.1
Exhibit 10.1
***
Exhibit 10.1
IN WITNESS WHEREOF, the Parties hereto have executed this Settlement Agreement as of the date first above written.
For Acasti Pharma Inc.:
/s/ Prashant Kohli Name: Prashant Kohli Title: Chief Executive Officer | For Aker BioMarine Antarctic AS:
/s/ Matts Johansen Name: Matts Johansen Title: Chief Executive Officer |
Exhibit 10.1
Appendix 1: Production Equipment Inventory List
Exhibit 10.1
Appendix 2: List of CaPre® Data
Exhibit 10.1
Appendix 3: List of CaPre® IP